Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 Inhibitor) and pemetrexed

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 660-667

  Soto, E ^a   Staab, A ^b   Freiwald, M ^b   Munzert, G ^b   Fritsch, H ^b   Doge C ^b   Troconiz I F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BIBF 1120; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CELL CYCLE PROTEIN; GLUTAMIC ACID DERIVATIVE; GUANINE; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG POTENTIATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; SIMULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; COMPUTER SIMULATION; FEASIBILITY STUDY; LUNG NEOPLASMS; METABOLISM; PHASE 1 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; FEASIBILITY STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEUTROPENIA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; TREATMENT OUTCOME;

EID: 77958498188     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.148     Document Type: Article

References (40)

1. Smits, V.A., Klompmaker, R., Arnaud, L., Rijksen, G., Nigg, E.A. & Medema, R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2, 672-676 (2000).
2. Mross, K. et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 26, 5511-5517 (2008).
3. Soto, E. et al. Semi-mechanistic population pharmacokinetic/ pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother. Pharmacol. (2010); e-pub ahead of print 9 January 2010.
4. Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20, 4713-4721 (2002).
5. Adjei, A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res. 10, 4276s-4280s (2004).
6. Hanna, N. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004).
7. Smit, E.F., Mattson, K., von Pawel, J., Manegold, C., Clarke, S. & Postmus, P.E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann. Oncol. 14, 455-460 (2003).
8. Ozawa, K., Minami, H. & Sato, H. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients. Cancer Sci. 98, 1985-1992 (2007).
9. Liu, W., Zhang, X. & Sun, W. Developments in treatment of esophageal/gastric cancer. Curr. Treat. Options Oncol. 9, 375-387 (2008).
10. Esteban, E., Casillas, M. & Cassinello, A. Pemetrexed in frst-line treatment of non-small cell lung cancer. Cancer Treat. Rev. 35, 364-373 (2009).
11. Carrick, S., Parker, S., Thornton, C.E., Ghersi, D., Simes, J. & Wilcken, N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst. Rev. CD003372 (2009).
12. Léger, F. et al. Mechanism-based models for topotecan-induced neutropenia. Clin. Pharmacol. Ther. 76, 567-578 (2004).
13. van Kesteren, C. et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest. New Drugs 23, 225-234 (2005).
14. Trocòniz, I.F. et al. Phase I dose-fnding study and a pharmacokinetic/ pharmacodynamic analysis of the neutropenic response of intravenous difomotecan in patients with advanced malignant tumours. Cancer Chemother. Pharmacol. 57, 727-735 (2006).
15. Latz, J.E., Karlsson, M.O., Rusthoven, J.J., Ghosh, A. & Johnson, R.D. A semimechanistic-physiologic population pharmacokinetic/ pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother. Pharmacol. 57, 412-426 (2006). (Pubitemid 43087584)
16. Kathman, S.J., Williams, D.H., Hodge, J.P. & Dar, M. A Bayesian population PK-PD model of ispinesib-induced myelosuppression. Clin. Pharmacol. Ther. 81, 88-94 (2007).
17. Puisset, F. et al. Clinical pharmacodynamic factors in docetaxel toxicity. Br. J. Cancer 97, 290-296 (2007).
18. Fetterly, G.J. et al. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin. Cancer Res. 14, 5856-5863 (2008).
19. Brain, E.G., Rezai, K., Lokiec, F., Gutierrez, M. & Urien, S. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study. Br. J. Clin. Pharmacol. 65, 607-610 (2008).
20. Sandström, M., Lindman, H., Nygren, P. , Lidbrink, E., Bergh, J. & Karlsson, M.O. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J. Clin. Oncol. 23, 413-421 (2005).
21. Sandström, M., Lindman, H., Nygren, P. , Johansson, M., Bergh, J. & Karlsson, M.O. Population analysis of the pharmacokinetics and the haematological toxicity of the fuorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother. Pharmacol. 58, 143-156 (2006).
22. Joerger, M. et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin. Cancer Res. 13, 6410-6418 (2007).
23. Zandvliet, A.S., Schellens, J.H., Dittrich, C., Wanders, J., Beijnen, J.H. & Huitema, A.D. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br. J. Clin. Pharmacol. 66, 485-497 (2008).
24. Kathman, S.J., Williams, D.H., Hodge, J.P. & Dar, M. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemother. Pharmacol. 63, 469-476 (2009).
25. Takimoto, C.H. et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin. Cancer Res. 13, 2675-2683 (2007)
26. Zamboni, W.C. et al. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin. Cancer Res. 7, 2301-2308 (2001).
27. Vainstein, V., Ginosar, Y., Shoham, M., Ranmar, D.O., Ianovski, A. & Agur, Z. The complex efect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J. Theor. Biol. 234, 311-327 (2005).
28. Woo, S., Krzyzanski, W. & Jusko, W.J. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother. Pharmacol. 62, 123-133 (2008).
29. Latz, J.E., Rusthoven, J.J., Karlsson, M.O., Ghosh, A. & Johnson, R.D. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother. Pharmacol. 57, 427-435 (2006). (Pubitemid 43087585)
30. Wallin, J.E., Friberg, L.E. & Karlsson, M.O. A tool for neutrophil guided dose adaptation in chemotherapy. Comput. Methods Programs Biomed. 93, 283-291 (2009).
31. Zandvliet, A.S., Schellens, J.H., Copalu, W., Beijnen, J.H. & Huitema, A.D. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J. Pharmacokinet. Pharmacodyn. 36, 39-62 (2009).
32. Zandvliet, A.S., Karlsson, M.O., Schellens, J.H., Copalu, W., Beijnen, J.H. & Huitema, A.D. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Invest. New Drugs 28, 61-75 (2010).
33. Latz, J.E., Schneck, K.L., Nakagawa, K., Miller, M.A. & Takimoto, C.H. Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: efect of vitamin supplementation and diferences between Japanese and Western patients. Clin. Cancer Res. 15, 346-354 (2009).
34. Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efcacy. Cancer Res. 68, 4774-4782 (2008).
35. Chow, S.C. & Chang, M. Adaptive Design Methods in Clinical Trials 277 (CRC Press, Boca Raton, FL, 2006).
36. Beal, S.L. & Sheiner, L.B. NONMEM Users Guides (Icon Development Solutions, Ellicott City, MD, 1989-2006).
37. Karlsson, M. & Holford, N.H. A tutorial on visual predictive checks [abstr 1434]. PAG E 17 (2008). .
38. Bergstrand, M., Hooker, A.C., Wallin, J. & Karlsson, M.O. Prediction corrected visual predictive checks. ACOP, American Conference on Pharmacometrics (2009). .
39. Minto, C.F., Schnider, T.W., Short, T.G., Gregg, K.M., Gentilini, A. & Shafer, S.L. Response surface model for anesthetic drug interactions. Anesthesiology 92, 1603-1616 (2000).
40. Gisleskog, P.O., Karlsson, M.O. & Beal, S.L. Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29, 473-505 (2002).